Simplicity Wealth LLC Raises Stock Position in Intuitive Surgical, Inc. $ISRG

Key Points

• Simplicity Wealth LLC increased its stake in Intuitive Surgical by 161.4% in Q2, bringing their total holdings to 3,631 shares worth approximately $1.97 million.
• Insider transactions revealed significant sales, with Gary S. Guthart selling 29,360 shares for over $13.8 million, indicating a 59.69% decrease in his position.
• Despite recent insider sales, analysts maintain a consensus rating of "Moderate Buy" for Intuitive Surgical, with a price target of $594.19.

Simplicity Wealth LLC boosted its stake in Intuitive Surgical, Inc. (NASDAQ:ISRG - Free Report) by 161.4% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 3,631 shares of the medical equipment provider's stock after purchasing an additional 2,242 shares during the period. Simplicity Wealth LLC's holdings in Intuitive Surgical were worth $1,973,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently modified their holdings of the stock. Brighton Jones LLC raised its holdings in shares of Intuitive Surgical by 24.9% during the 4th quarter. Brighton Jones LLC now owns 3,672 shares of the medical equipment provider's stock valued at $1,916,000 after buying an additional 731 shares during the period. NBC Securities Inc. acquired a new stake in Intuitive Surgical in the first quarter valued at approximately $135,000. Vest Financial LLC raised its stake in shares of Intuitive Surgical by 73.5% during the first quarter. Vest Financial LLC now owns 4,728 shares of the medical equipment provider's stock valued at $2,342,000 after purchasing an additional 2,003 shares during the period. Pines Wealth Management LLC acquired a new position in shares of Intuitive Surgical during the first quarter worth $216,000. Finally, Sivia Capital Partners LLC boosted its stake in shares of Intuitive Surgical by 7.5% in the first quarter. Sivia Capital Partners LLC now owns 894 shares of the medical equipment provider's stock valued at $443,000 after purchasing an additional 62 shares during the period. Institutional investors and hedge funds own 83.64% of the company's stock.

Insider Activity

In other Intuitive Surgical news, insider Gary S. Guthart sold 29,360 shares of the firm's stock in a transaction dated Friday, August 29th. The shares were sold at an average price of $472.49, for a total transaction of $13,872,306.40. Following the transaction, the insider owned 19,827 shares of the company's stock, valued at approximately $9,368,059.23. This trade represents a 59.69% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, EVP Myriam Curet sold 4,500 shares of the business's stock in a transaction dated Friday, July 25th. The stock was sold at an average price of $492.48, for a total transaction of $2,216,160.00. Following the sale, the executive vice president owned 353 shares in the company, valued at $173,845.44. This trade represents a 92.73% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 45,224 shares of company stock valued at $21,716,492. Company insiders own 0.70% of the company's stock.

Intuitive Surgical Trading Up 2.1%

NASDAQ ISRG opened at $452.35 on Monday. The company has a 50-day moving average price of $463.55 and a two-hundred day moving average price of $500.11. The stock has a market cap of $162.16 billion, a price-to-earnings ratio of 63.09, a price-to-earnings-growth ratio of 4.74 and a beta of 1.61. Intuitive Surgical, Inc. has a 52 week low of $425.00 and a 52 week high of $616.00.

Intuitive Surgical (NASDAQ:ISRG - Get Free Report) last issued its quarterly earnings data on Tuesday, July 22nd. The medical equipment provider reported $2.19 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.93 by $0.26. Intuitive Surgical had a return on equity of 14.56% and a net margin of 28.51%.The business had revenue of $2.44 billion during the quarter, compared to the consensus estimate of $2.35 billion. During the same period in the previous year, the firm posted $1.78 earnings per share. The business's revenue was up 21.4% on a year-over-year basis. As a group, equities research analysts expect that Intuitive Surgical, Inc. will post 6.43 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several equities research analysts recently issued reports on ISRG shares. Weiss Ratings reaffirmed a "hold (c+)" rating on shares of Intuitive Surgical in a research note on Saturday, September 27th. Deutsche Bank Aktiengesellschaft reaffirmed a "sell" rating on shares of Intuitive Surgical in a research report on Friday, August 22nd. Evercore ISI increased their price target on Intuitive Surgical from $470.00 to $550.00 and gave the company an "in-line" rating in a report on Tuesday, July 8th. Truist Financial lifted their price objective on Intuitive Surgical from $590.00 to $600.00 and gave the stock a "buy" rating in a report on Wednesday, July 23rd. Finally, Piper Sandler reaffirmed an "overweight" rating and issued a $595.00 target price (up from $575.00) on shares of Intuitive Surgical in a research report on Wednesday, July 23rd. Fourteen analysts have rated the stock with a Buy rating, seven have given a Hold rating and one has issued a Sell rating to the company's stock. According to data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and a consensus price target of $594.19.

Intuitive Surgical Company Profile

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.